Electromed, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum
Electromed, Inc. (ELMD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum of 4.14% for the 6-month period ending 2024-12-31, per its 10-Q filed 2025-02-11.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum · last filed 2025-02-11
- Electromed, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for the quarter ending 2023-09-30 was 4.43%.
- Electromed, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2023 was 4.23%, a 67.86% increase from fiscal 2022.
- Electromed, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2022 was 2.52%, a 327.12% increase from fiscal 2021.
- Electromed, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2021 was 0.59%.
- Electromed, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate, maximum for fiscal 2013 was 1.80%, a 5.26% decline from fiscal 2012.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | 4.14% 10-Q · filed 2025-02-11 | ||||
| 2024-06-30 | 4.64% 10-Q · filed 2025-02-11 | ||||
| 2024-03-31 | 4.64% 10-Q · filed 2024-05-07 | ||||
| 2023-12-31 | 4.64% 10-Q · filed 2024-02-13 | ||||
| 2023-09-30 | 4.43% 10-Q · filed 2023-11-07 | ||||
| 2023-06-30 | 4.23% 10-K · filed 2024-08-27 | ||||
| 2023-03-31 | 4.23% 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | 4.23% 10-Q · filed 2023-02-14 | ||||
| 2022-06-30 | 2.52% 10-K · filed 2023-08-22 | ||||
| 2022-03-31 | 1.93% 10-Q · filed 2022-05-10 | ||||
| 2021-12-31 | 1.07% 10-Q · filed 2022-02-08 | ||||
| 2021-06-30 | 0.59% 10-K · filed 2022-08-23 | ||||
| 2017-06-30 | 1.27% 10-Q · filed 2018-05-08 | ||||
| 2013-06-30 | 1.80% 10-K · filed 2014-09-23 | ||||
| 2012-06-30 | 1.90% 10-K · filed 2013-09-25 | 1.93% 10-K · filed 2012-09-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| EDAP TMS SA (FOCL) | $0.171B | ||
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B | |
| Nexalin Technology, Inc. (NXL) | United States | $0.094B | |
| Streamex Corp. (STEX) | United States | $0.089B | -0.19 |
| Outset Medical, Inc. (OM) | United States | $0.059B | -1.09 |
| PRECISION OPTICS CORPORATION, INC. (POCI) | United States | $0.052B |